24-week data from a phase IIIb US study have confirmed the safety and tolerability of tocilizumab (either 8 mg/kg alone or 4 mg/kg or 8 mg/kg in combination with nonbiologic DMARDs) for patients with moderate-to-severe rheumatoid arthritis. The adverse event profile of tocilizumab in the 866 patients analysed was similar to previous results, with the most common serious complication being infection.
ORIGINAL RESEARCH PAPER
Weinblatt, M. E. et al. Tocilizumab as monotherapy or in combination with nonbiologic DMARDs: a 24-week results of an open-label, clinical practice study (ACT-STAR). Arthritis Care Res. doi:10.1002/acr.21847
Rights and permissions
About this article
Cite this article
Safety profile of tocilizumab confirmed. Nat Rev Rheumatol 8, 633 (2012). https://doi.org/10.1038/nrrheum.2012.173
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.173